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Abstract
Recent investigations on the effects of phyto-oestrogens on various tissues
have revealed that these diverse molecules may improve human health,
particularly by protecting against certain chronic diseases. After a brief
examination of the food sources, structures, and general cellular actions of
the major phyto-oestrogens, current research ®ndings on cardiovascular
disease, skeletal tissues, and reproductive cancers are reviewed. Phyto-
oestrogen concentrations in blood may be maintained at high levels in
those consuming soyabean (Glycine max)-based food daily at several
meals and exert their effects on target cells through either genomic effects
via the classical oestrogen receptors or non-genomic effects mediated by
membrane-bound oestrogen receptors or other cellular proteins. The
expression of oestrogen receptor (OR) subtypes alpha (a) and beta (b)
varies across tissues, and cells that preferentially express OR-b, which
may include bone cells, are more likely to respond to phyto-oestrogens.
Conversely, reproductive tissues contain relatively more OR-a and may,
thus, be differently affected by phyto-oestrogens. Soyabean phyto-
oestrogens appear to prevent the progression of atherosclerosis through
multiple interactions, including lowering of plasma lipids and lipoproteins,
increased vasodilatation and, possibly, decreased activation of blood
platelets and vascular smooth muscle cells. However, a favourable impact
on cardiovascular disease morbidity and mortality by a soyabean-enriched
western-type diet remains to be shown, and unresolved questions remain
regarding dose and form of the phyto-oestrogens in relation to risks and
bene®ts. The iso¯avones of soyabean have been shown consistently to
have bone-retentive effects in animal studies by several investigators using
rodent models, although intakes must be above a relatively high threshold
level for a lengthy period of time, and little or no extra bene®t is observed
with intakes above this threshold level. The reports of modest or no effects
on prevention of bone loss in human and non-human primate studies
respectively, may be due to the limited doses tested so far. The relation-
ship between soyabean-food intake and cancer risk has been more
extensively investigated than for any other disease, but with less certainty
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about the bene®ts of long-term consumption of phyto-oestrogen-contain-
ing foods on prevention of cancer. The observations that breast and
prostate cancer rates are lower in Asian countries, where soyabean foods
are consumed at high levels, and the high iso¯avone content of soyabeans
have led to examination of the potential protective effects of phyto-
oestrogens. Establishing diet±cancer relationships has proved dif®cult,
in part because of the con¯icting data from various studies of effects
of soyabean-diets on cancer. Epidemiological evidence, though not
impressive, does suggest that soyabean intake reduces breast cancer risk.
The iso¯avone genistein has a potent effect on breast cancer cells in vitro,
and early exposure of animals to genistein has been effective in reducing
later development of mammary cancer. Thus, continuous consumption of
soyabean foods in early life and adulthood may help explain the low breast
cancer mortality rates in Asian countries. Although the evidence for a
protective effect against prostate cancer may be slightly more supportive,
more research is needed before any ®rm conclusions can be made about
the phyto-oestrogen±cancer linkages.
Phyto-oestrogens: Soyabean : Cancer: Bone: Blood lipids
Introduction
Practically all plant foods contain small amounts of the diverse phyto-oestrogen molecules that
have the potential to improve health. Phyto-oestrogens, especially the soyabean-derived iso-
¯avones, are receiving great scrutiny as food supplements for the purposes of both enhancing
the health of tissues and preventing several common diseases, such as cardiovascular diseases,
cancers of reproductive tissues, and osteoporosis. Food phyto-oestrogen molecules can be
divided into two major chemical classes: iso¯avones and coumestans. The iso¯avones are
found predominantly in soyabeans (Glycine max), whereas coumestans are produced primarily
by clovers (genus Trifolium) and some legumes. These molecules function as antioxidants in
plants, but in mammalian tissues these natural products act as agonists, or partial agonists, of
oestrogens.
This review covers the following topics relating to phyto-oestrogens: food sources, general
cellular actions, effects on cardiovascular and skeletal tissues, and cancer chemoprevention.
Food sources of phyto-oestrogens
Relatively few foods contribute signi®cant amounts of phyto-oestrogens to the human diet, and
the cultural variation in consumption of those foods, particularly soyabean products, results in a
wide range of intakes of these molecules. The use of soyabean products in Asian nations
contributes to the highest levels of phyto-oestrogens measured in human subjects, e.g. Japanese
men and women have intakes that are ten-fold or greater than those of the USA population
average (Adlercreutz et al. 1993; Messina, 1995).
Phyto-oestrogens, both iso¯avones and coumestans, are present in a variety of legumes
consumed by Americans. The highest concentration of the major iso¯avones (genistein and
daidzein) are found in soyabeans and soyabean products as shown in Fig. 1 for genistein and
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daidzein. Clearly the concentrations of iso¯avones in the derivative or second generation
soyabean foods are lower than those of the soyabeans themselves or soyabean products made
directly from soyabeans. The concentration of iso¯avones decreases in the derivative soyabean
foods because of dilution with other constituents and losses during processing. For instance,
many of the second generation soyabean products are made from soyabean concentrate that has
been extracted with ethanol to make the food more palatable. The aqueous±ethanol extraction
method can remove > 90 % of the iso¯avones, although less rigorous extraction methods are
generally used. The iso¯avones appear to be resistant, however, to degradation by commonly
used food preparation methods, e.g. baking, frying, etc.
While coumestrol is an important phyto-oestrogen in animal diets, the coumestans are
present in only a few foods commonly consumed by humans. Table 1 lists those foods that
contain potentially signi®cant amounts of coumestrol, the primary coumestan consumed by
humans.
Food processors and manufacturers of dietary supplements have obviously become aware
of the interest in the potential bene®ts of phyto-oestrogen consumption on prevention of car-
diovascular disease, cancer, and osteoporosis. The available data consist of a mixture of epi-
demiological studies examining the relationship between consumption of natural foods
Fig. 1. Iso¯avone contents of various soyabean products. Iso¯avone contents of soyabean
foods are expressed as mg=kg food (wet wt.) (j), Genistein; ( ), daidzein. Note that the
genistein : daidzein ratio is approximately 3 : 2 to 2 : 1 for a variety of soyabean foods. Taken
from Coward et al. (1993) and Wang & Murphy (1994).
Table 1. Coumestrol content of foods*
Food item Coumestrol (mg=kg)
Clover (genus Trifolium) sprouts 2806
Round split peas (Pisum sativum), dry 811
Kala chana (Cicer arietinum) 613
Lucerne (Medicago sativa) sprouts 468
Pinto bean (Phaselous vulgaris) seeds, dry 361
Large lima bean (Phaselous limensis) seeds, dry, raw 148
* From Franke et al. (1994).
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containing phyto-oestrogens and disease prevalence, a relatively few studies of human subjects
in which puri®ed or enriched phyto-oestrogen preparations are taken prospectively, and a
burgeoning number of animal and in vitro studies. The increased availability of iso¯avone-
enriched supplements and new food items containing signi®cant amounts of natural or sup-
plemented phyto-oestrogens will probably lead to an increase in consumption of these mole-
cules by the population. Because of the connection of the phyto-oestrogens with reduced risk of
osteoporosis and cancer, particularly breast cancer, women are more likely to choose to
increase their consumption of these dietary molecules.
Structures of major phyto-oestrogens
The phyto-oestrogens can interact with oestrogen receptors, and the similarity of their struc-
tures to the 17b-oestradiol molecule is believed to explain this mimicry. These molecules share
several features in common with the oestradiol structure (Fig. 2), including a pair of hydroxyl
groups separated at a similar distance; one hydroxyl group is a substituent of an aromatic A ring
while the second hydroxyl lies at the opposite end of the molecule (Miksicek, 1993).
The oestrogen-like structures of the phyto-oestrogens help explain the ability of these
molecules to occupy the oestrogen receptor; however, the interaction is not equivalent since
both the occupancy time and af®nity for the receptor are signi®cantly reduced for phyto-
oestrogens (Miksicek, 1994). In addition, small differences in the structures of individual
iso¯avones dramatically alter their oestrogenicity. Daidzein and genistein share identical
structures except for an additional hydroxyl group on the A ring of genistein; however, gen-
istein may have up to 5±6-fold greater oestrogenic activity in some assays (Markiewicz et al.
1993).
The iso¯avones are present in foods in multiple chemical forms. The aglycone form is
considered the active form of the molecules, but they may be only a small percentage of the
total iso¯avones. The glucoside (glycone) form and acetyl- and malonylglucosides are the
Fig. 2. Chemical structures of the major phyto-oestrogen molecules in comparison with 17b-
oestradiol. The phyto-oestrogens are drawn with the B ring up to emphasize the similarity to the
oestradiol molecule.
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major forms found in soyabean and soyabean products. Some of the fermented soyabean
products, such as fermented bean curd, have aglycones as the major iso¯avone form (Wang &
Murphy, 1994). The conversion of iso¯avones from glucosides to aglycones is accomplished in
the gut, and metabolism also includes generation of the primary iso¯avone molecules, genistein
and daidzein, from precursors with lower oestrogenicity (Fig. 3). Biochanin A and for-
mononetin, found in clover sprouts and a few other legumes, are readily converted by gut ¯ora
to genistein and daidzein respectively. Genistein can be further metabolized in the gut to
compounds such as 4-ethylphenol, and daidzein to compounds such as equol, dihydrodaidzein,
and O-desmethylangolensin. Although genistein and daidzein have been used for most
experimental studies of iso¯avone action, data suggest that the daidzein metabolite equol may
also exert signi®cant biological effects (Hodgson et al. 1996). Equol, which has a greater
antioxidant effect than other phyto-oestrogens, is often the iso¯avone found in highest con-
centration in the blood and urine.
General cellular actions of phyto-oestrogens
Cells containing large numbers of oestrogen receptors (OR), speci®cally breast and uterine
cells, were studied initially in an attempt to understand better the actions of speci®c phyto-
oestrogens. The original observations that female sheep became reproductively inef®cient
following the ingestion of fresh subterranean clover (Trifolium subterraneum) led Australian
scientists to conclude that excesses of coumestan-rich clover exerted adverse effects on uterine
and possibly ovarian function (Bennetts, 1946).
Other investigators have demonstrated that the amounts of phyto-oestrogens required to
produce classical oestrogenic effects on reproductive tissues similar to that of a physiological
dose of 17b-oestradiol are approximately 1000-fold or greater in experimental animal models.
In isolated cell lines of bone cells, however, the amounts of phyto-oestrogens required for
equivalent effects of 17b-oestradiol may be about the same (JJB Anderson, T Ohue and SC
Garner, unpublished results). This signi®cant difference in the effects of oral dosages,
approximately 10ÿ3 or greater, could result both from inef®cient absorption of the bioactive
Fig. 3. Phyto-oestrogen metabolism. Daidzein, the aglycone form of this phyto-oestrogen, may
be derived from intestinal metabolism of the aglycone or other precursor molecules. Further
metabolism of the phyto-oestrogen may also yield metabolites with oestrogenic activity, e.g.
equol.
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molecules (Xu et al. 1995) and differential effects of these compounds in various tissues
(Anthony et al. 1996; Anderson et al. 1998).
Once the fat-soluble phyto-oestrogens are delivered from the gut to the tissues via chylo-
microns, they have two potential fates at the cellular level: (1) they are taken up by passive
diffusion across the cell membrane and act via the classical oestrogen mechanism as weak
agonists; or (2) they interact with membrane proteins (receptors) and exert an effect that is
expressed through second messengers in the cytoplasm (see below).
The classical action of phyto-oestrogens, using genistein as the model molecule, consists of
several steps: combination with OR in the cytosol, movement of the genistein±OR complex
into the nucleus for activation of the oestrogen response element after dimerization with one of
several possible molecules, stimulation of DNA-directed mRNA synthesis, and the production
of new protein molecules speci®c to the tissue cell-type (Fig. 4).
Oestrogen regulation of genes has also been shown to involve an alternative pathway in
which the occupied oestrogen receptor combines with c-Fos and c-Jun oncoproteins and reg-
ulates gene transcription via AP-1 sites (Gaub et al. 1990; Weisz & Rosales, 1990; Umayahara
et al. 1994).
Since the discovery of a second type of OR, OR-b (Kuiper et al. 1996), tissues have been
found to vary in their expression of OR-a and OR-b. Some cells, especially breast and uterus,
have been reported to be rich in OR-a, whereas others, such as bone, are rich in OR-b (Kuiper
et al. 1997; Onoe et al. 1997), although this description may be an oversimpli®cation. A dif-
ferential distribution of OR, which have varying af®nities for oestrogen agonists, may be part of
the explanation for the dissimilar responses of various tissues to any single oestrogen agonist
and the altered response of a single tissue to different oestrogenic molecules. For example, a
selective oestrogen receptor modulator (SORM), like raloxifene, has little effect on repro-
Fig. 4. Classical genomic mechanism through which oestrogens and phyto-oestrogens act.
Binding of the oestrogen or phyto-oestrogen molecule, e.g. genistein, to the nuclear oestrogen
receptor initiates dimerization of the receptor and interaction with oestrogen response elements
on DNA. Activation or inhibition of gene transcription results in altered protein expression. Binding
of a phyto-oestrogen may be interpreted to result in either a weakly oestrogenic effect or an anti-
oestrogenic effect based on displacement of oestrogen molecules.
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ductive tissues, but has bone-conserving properties. (These diverse properties of molecules with
oestrogenic activity has led to the generation of the term SORM.) Phyto-oestrogens, especially
genistein, are thought to act like SORM, although additional experimental work is needed to
clarify the actions of speci®c phyto-oestrogens on OR.
Phyto-oestrogens have generally been reported to have lower binding af®nity for oestrogen
receptors (Miksicek, 1994) and lower potency in producing oestrogenic effects (Markiewicz et
al. 1993) compared with 17b-oestradiol. As shown in Table 2, the relative binding af®nities
with the oestrogen receptor and relative potencies in inducing alkaline phosphatase (EC 3.1.3.1)
activity in endometrial adenocarcinoma cells in culture have a similar rank order for major
phyto-oestrogens. The values for relative binding af®nities of phyto-oestrogens, however, tend
to be several-fold higher compared with oestradiol than the corresponding potency in the
endometrial cell line. Other cell types, including cells of the cardiovascular system, bone cells,
and cancer cells of many different tissues may have different responses to the various phyto-
oestrogens.
Steroid molecules, which include oestrogen and the other sex hormones, adrenal steroids,
and 1,25-dihydroxyvitamin D, have recently been suggested to have effects on membrane-
bound receptors that do not involve activation of the genomic machinery of the cell (Nemere,
1995, 1996; Machelon et al. 1996; Benten et al. 1997; Le Mellay et al. 1997). Several
researchers have reported that addition of 17b-oestradiol to osteoblasts and other cells in
culture stimulates increases in intracellular Ca2 within seconds to minutes (Picotto et al.
1996; Le Mellay et al. 1997; Benten et al. 1998). The changes in this potential intracellular
second messenger are much too rapid to involve changes in protein synthesis via the nuclear
steroid receptors. Although it has not been demonstrated experimentally, phyto-oestrogens
probably are also recognized by the putative cell-surface oestrogen receptors. In addition, other
effects of phyto-oestrogens that involve activation of several possible second messengers,
including kinase enzymes, may in turn stimulate or inhibit downstream pathways of metabo-
lism and protein products. Many of these potential mechanisms of action of phyto-oestrogens
are illustrated in Fig. 5.
The duration of the effects of phyto-oestrogens mediated via an interaction with membrane
protein(s) is considered to be short-lived and with limited ef®cacy, unless the stimulating
molecules are continuously available in solutions bathing cells. In studies of isolated cells in
culture in which the media are frequently exchanged, the continuous dosing of cells with a
phyto-oestrogen is easy to visualize. In animal models or humans, it is less certain that suf®-
Table 2. Relative binding af®nities and relative potencies of major phyto-oestrogens compared with 17b-
oestradiol





Biochanin A 000005 <0000006
* Adapted from Miksicek (1994). The relative binding af®nities are calculated as the inverse of the concentration excess,
relative to 17b-oestradiol, required to give 50 % inhibition of speci®c binding of 17b- [3H]oestradiol to oestrogen
receptors expressed in COS-7 cells, e.g. a 20 000-fold excess of biochanin A is required for 50 % inhibition.
{ Adapted from Markiewicz et al. (1993). The relative potencies are based on the concentrations of phyto-oestrogens
that exert one-half of their maximum effects (EC50) on alkaline phosphatase (EC 3.1.3.1) in endometrial
adenocarcinoma cells (Ishikawa-Var I) with the potency of oestradiol set at 1.0.
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ciently high blood concentrations can be maintained over long periods, i.e. weeks to months, to
have a signi®cant impact on cells. Studies of isolated immortal osteoblast-like cells (ROS and
ROS.SMER) treated with genistein suggest that the membrane mechanism of action can
modestly, but signi®cantly, upregulate the cellular production of alkaline phosphatase
approximately 20±30 % above basal unstimulated production (JJB Anderson, T Ohue and SC
Garner, unpublished results). At the same time, genistein appears to have little or no effect on
the classical OR mechanism in these cells, as shown by lack of any inhibitory effect of the pure
oestrogen antagonist, ICI 182,780 (during the ®rst 4±6 d in culture) (JJB Anderson, T Ohue and
SC Garner, unpublished results).
In summary, both true oestrogens and phyto-oestrogens exert their effects on target cells
containing viable OR by two mechanisms, the classical OR-induced series of steps, and the new
membrane-protein interaction. Elevated concentrations of oestrogens can be maintained
throughout fairly long periods, such as during parts of the menstrual cycle and during preg-
nancy. Similarly, phyto-oestrogen concentrations in blood may also be maintained at fairly high
levels by ingestion of soyabean products at several meals each day, as is the case of many
Japanese who consume 30±50 g soyabean-containing foods=d (Adlercreutz et al. 1993; Mes-
sina, 1995). Therefore, exposure of cells to oestrogens and=or phyto-oestrogens during these
periods would be presumed to activate both the OR and the membrane proteins. Tissues with
greater numbers of OR-a, e.g. breast and uterus, would probably be more affected by true
oestrogens than by phyto-oestrogens, but tissues with higher expression of OR-b (e.g. bone)
might be more responsive to phyto-oestrogens.
Effects of phyto-oestrogens on cardiovascular disease and its risk factors
Phyto-oestrogens have recently been shown to have several effects on cardiovascular tissues.
These effects may reduce the risk of cardiovascular diseases.
Fig. 5. Non-genomic mechanisms through which oestrogens and phyto-oestrogens may act.
Oestrogens and phyto-oestrogens may bind to the postulated cell-surface oestrogen receptor to
alter cellular activity. Phyto-oestrogens, particularly genistein, may have other effects via inhibition
of tyrosine kinase (EC 2.7.1.112) activity, quenching of free radicals, or inhibition of topoisome-
rase II (EC 5.99.1.3), which alters the cell cycle.
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Effects of soyabean protein on plasma lipids and atherosclerosis
The replacement of animal protein in the diet with soyabean protein has long been associated
with hypocholesterolaemic and atherosclerosis-preventive effects (Meeker & Kesten, 1941).
Anderson et al. (1995b) have reported on a meta-analysis assessing the effects of dietary
soyabean protein on plasma lipid concentrations in which soyabean protein supplementation
resulted in a reduction of approximately 13 % in plasma LDL-cholesterol concentrations, 11 %
reduction in plasma triacylglycerol, and 2 % increase in HDL-cholesterol. If one strati®es the
results by baseline total plasma cholesterol concentrations, the effects of dietary soyabean
protein supplementation on total cholesterol and LDL-cholesterol concentrations are most
robust among those with the highest plasma cholesterol at baseline. Recently, Nagata et al.
(1998) reported a signi®cant trend for lower plasma cholesterol concentrations with increasing
soyabean intake after adjustment for potential confounders for both men (n 1242, P for
trend 00001) and women (n 3596, P for trend 00001) in a prospective cohort study in
Takayama City, Japan. These studies suggest that soyabean proteins may be useful for
improving plasma lipoprotein concentrations and for prevention of cardiovascular disease.
Cardiovascular protective components of soyabean
While the cardioprotective effects of soyabean protein are well accepted, the component(s)
responsible for these effects is currently the subject of much research. During the 1970s and
early 1980s the amino acid composition was investigated for its effect on plasma lipid and
lipoprotein metabolism and its role in atherosclerosis inhibition.
Huff et al. (1977) reported one such study that seems to re¯ect the overall ®ndings of these
studies. Groups of rabbits (n 6±10 per group) were fed on diets that contained either casein or
soyabean protein or mixtures of amino acids that duplicated the amino acid composition of each
protein.For casein or its amino acid mixture the plasma cholesterol concentrationsof the twogroups
werefoundtobeessentially thesame.However, forsoyabeanprotein theaminoacidmixturewasnot
as hypocholesterolaemic as the intact protein, providing evidence that there were components of the
intact soyabean other than the amino acids that independently lowered plasma cholesterol con-
centrations or interacted with the protein moiety to affect lipoprotein metabolism favourably.
More recently, evidence has accumulated that the component of soyabean protein responsible
for a large part of its cardioprotective effects is an alcohol-extractable molecule(s) (Sugano &
Koba, 1993; Anthony et al. 1996, 1997; Balmir et al. 1996; Kirk et al. 1998; Tovar-Palacio et al.
1998). The alcohol-extractable components that may have the potential to lower plasma lipid
concentrations are the saponins, phytosterols and iso¯avones. The bulk of evidence regarding
saponins is that they exert no hypocholesterolaemic effect in the presence of soyabean protein
(Potter et al. 1993). In addition, most soyabean protein isolates have low amounts of phytosterols
because of delipidation and extensive processing required to obtain the isolates (Anderson & Wolf,
1995). The iso¯avones (non-steroidal phyto-oestrogens), which are largely removed from soya-
bean protein when it is washed with alcohol, have been reported to alter plasma lipid concentrations
and are currently being actively investigated for their role in cardiovascular disease protection.
Effects of soyabean phyto-oestrogens on plasma lipids and lipoproteins
Several studies provide evidence that the phyto-oestrogens in soyabean modulate plasma lipid
and lipoprotein concentrations, but the data are not entirely consistent. For the purpose of this
review, only published reports for which the study design allows an assessment of the iso-
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¯avones (phyto-oestrogens) as the likely mediating factor on cardiovascular endpoints will be
included.
In one report (Balmir et al. 1996), rats (n 6 per group) were fed for 28 d on diets containing
soyabean protein extracted with ethanol to remove the phyto-oestrogens (soya(ÿ)), unextracted
soyabean protein with the phyto-oestrogens intact (soya( )), casein (casein), or casein with
0.36 mg alcohol-extract of soyabean ¯our added per g protein (casein( ). The alcohol-extract
was treated with acetone to precipitate sugars, saponins and proteins; thus it was principally a
phyto-oestrogen-containing extract. All of the diets contained moderate amounts of fat, pre-
dominantly saturated fats, and were cholesterol-free. The groups fed on the casein( ), soya(ÿ),
and soya( ) diets had signi®cantly lower LDL-cholesterol concentrations than the casein
group, but the former three groups were not signi®cantly different from each other. The HDL-
cholesterol concentrations tended to be higher in the two groups fed on the diets containing
iso¯avones relative to the iso¯avone-devoid groups. In a second study (Balmir et al. 1996) with
hamsters (n 10 per group), the casein, casein( ), and soya( ) diets were the same as described
earlier. Two additional groups were included in this study, a group fed on the unextracted
soyabean protein with 0.36 mg iso¯avone-containing extract added per g protein (soya( ))
and a group fed on casein with 0.72 mg extract added per g protein (casein( )). The effects
of all these diets on LDL- VLDL-cholesterol concentrations were examined. The soya( ),
soya( ), and casein( ) groups had signi®cantly lower LDL- VLDL-cholesterol con-
centrations than the casein group. The LDL- VLDL-cholesterol concentration of the case-
in( ) group was also lower than for the casein group but not signi®cantly so.
Therefore, while both soyabean protein and the iso¯avone-containing extract lowered
LDL- VLDL-cholesterol concentrations, no additional bene®t was seen for the groups
receiving the higher dose of iso¯avone extract (casein( ) and soya( )) in these two
species.
Kirk et al. (1998) have reported on a study in which they fed diets containing unextracted
soyabean protein isolate (soya( )) or alcohol-washed soyabean protein (soya(ÿ)) to C57BL=6
(wild-type) mice and LDL receptor-de®cient (LDLr-null) mice. The wild-type (soya(ÿ), n 16;
soya( ), n 20) were treated for 10 weeks and the LDLr-null groups (soya(ÿ), n 9; soya( ),
n 8) for 6 weeks. Among the wild-type mice the soya( ) group had signi®cantly lower total
and LDL- VLDL- cholesterol concentrations than the soya(ÿ) group. HDL-cholesterol
concentrations were not different between groups. Among the LDLr-null mice, no signi®cant
difference was observed in total plasma cholesterol between diet groups. The authors inter-
preted these differences in response of the two strains of mice to suggest that soyabean iso-
¯avones might lower plasma cholesterol concentrations by increasing LDL receptor activity,
thus the lack of effect of the iso¯avone-containing soyabean protein to lower plasma choles-
terol in the LDL receptor-de®cient mice.
Studies in non-human primates support the hypothesis that soyabean phyto-oestrogens play
a primary role in modulating plasma lipid and lipoprotein concentrations (Anthony et al. 1996,
1997, 1998). In a cross-over study in young rhesus monkeys (Macaca mulatta) (n 25), the
animals were fed on diets containing soyabean protein isolate from which the iso¯avones had
been extracted with ethanol (soya(ÿ)) or with the iso¯avones intact (soya( )) (Anthony et al.
1996). Plasma LDL- VLDL-cholesterol concentrations were signi®cantly lower with the
soya( ) diet in both males and females. Additionally, in the females the soya( ) diet con-
sumption resulted in signi®cantly improved HDL-cholesterol concentrations relative to when
they were fed on the soya(ÿ) diet.
In another study with non-human primates (Anthony et al. 1997, 1998), young cynomolgus
monkeys (Macaca fasicularis) (males, n 77; females, n 70) were fed on diets containing either
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casein and lactalbumin (casein), alcohol-extracted soyabean protein isolate (soya(ÿ)), or
unextracted soyabean-protein isolate (soya( )) as the source of protein. The diets were
identical for other components. During the 14-month treatment period, plasma lipid con-
centrations were measured. There was a robust LDL- VLDL-cholesterol-lowering effect and
HDL-cholesterol-raising effect (P 00001) of the phyto-oestrogen-intact soyabean protein
relative to the phyto-oestrogen-extracted soyabean observed in both males and females
(P 00001 for the combined data for each measure). A large part of the bene®t of soyabean
protein is lost when it is alcohol-washed. It seems likely that the loss of the bene®cial effects of
soyabean protein isolate on plasma lipids and lipoproteins is due to the extraction of the phyto-
oestrogens.
Additional support for the hypothesis that the iso¯avones are an important modulator of
plasma lipoprotein concentrations comes from a recently completed study by Crouse et al. (1998).
In this randomized clinical trial, mildly hypercholesterolaemic men (n 94) and women (n 62) were
treated with protein supplements (25 g protein in each) that contained casein, alcohol-extracted
soyabean protein isolate (3 mg iso¯avones), or soyabean protein isolate that contained 27 mg,
37 mg, or 62 mg iso¯avones=d. The treatment phase lasted 9 weeks. The 62 mg iso¯avone group
(soya( )) had signi®cantly lower LDL-cholesterol concentrations than the casein group
(P< 0.05) while the alcohol-extracted soyabean protein (soya(ÿ)) had no effect. The authors also
reported a dose±response relationship with progressively lower total and LDL-cholesterol con-
centrations with increasing iso¯avone dose.
Baum et al. (1998) recently completed a study comparing the effects of soyabean protein
isolate containing two different concentrations of iso¯avones with a control protein (casein and
non-fat dry milk) in postmenopausal women (total n 66). All subjects received 40 g protein=d
and the iso¯avone doses for the two soyabean protein groups were 56 mg=d (soya( )) or
90 mg=d (soya( )). The soya( ) protein was similar in iso¯avone content to that used in
the study described earlier by Crouse et al. (1998). The difference in iso¯avone dose with this
product, 90 mg=d for Baum et al. (1998) and 62 mg=d for Crouse et al. (1998), results from the
difference in the amount of protein given each day, 40 g v. 25 g, respectively. Both doses of
iso¯avones resulted in signi®cantly lower LDL- VLDL-cholesterol and higher HDL-chol-
esterol concentrations relative to the control group. No evidence was found of a dose±response
effect on these endpoints.
The bene®cial effects of soyabean phyto-oestrogens on plasma lipids and lipoproteins
appear convincing. The LDL cholesterol-lowering effects of soyabean iso¯avones have been
shown in various animal models, including mice, rats, hamsters, cynomolgus and rhesus
monkeys, and human subjects. The LDL-cholesterol-lowering effects have been seen when
iso¯avone-containing extracts have been added to casein-based diets, a signi®cant attenuation
of LDL-cholesterol lowering has been demonstrated when the iso¯avones are removed
from soyabean protein by alcohol extraction, and a dose±response effect on LDL-
cholesterol lowering has been shown with increasing iso¯avone concentration in the dose
range of 3±62 mg iso¯avones=d. Studies with transgenic mice suggest that the bene®ts of
iso¯avones on cholesterol lowering may be mediated through upregulation of LDL-receptor
activity.
Effects of soyabean phyto-oestrogens on vascular reactivity
Vascular reactivity in response to acetylcholine is a measure of vascular function and can be
evaluated by repeated quantitative angiography. Changes in the diameter of a coronary artery
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are measured after intracoronary infusion of acetylcholine, which induces endothelium-medi-
ated vasodilation in normal arteries and constriction in atherosclerotic arteries of oestrogen-
de®cient subjects. HonoreÂ et al. (1997) compared the effects of unextracted soyabean protein
isolate (soya( ), n 5) and phyto-oestrogen-extracted soyabean protein (soya(ÿ), n 6) in young
pre- and peripubertal rhesus monkeys and reported that the soya( ) diet signi®cantly improved
vascular reactivity. They also repeated this test in the soya(ÿ) group and administered genistein
(the principal phyto-oestrogen in the soyabean protein isolate) intravenously 20 min before
angiography and found that genistein had similar oestrogen-like effects on vascular reactivity
(vasodilatation) relative to soya(ÿ) treatment. These data further support the hypothesis that the
phyto-oestrogens, and genistein in particular, are the components in soyabean responsible for
cardioprotection.
Effects of soyabean phyto-oestrogens on atherosclerosis
A much smaller body of experimental evidence supports a protective effect of soyabean phyto-
oestrogens on atherosclerosis. One piece of evidence is from a study of young cynomolgus
monkeys in which the animals were fed on diets containing either casein and lact-albumin,
alcohol-extracted soyabean-protein isolate (soya(ÿ)), or unextracted soyabean protein isolate
(soya( )) as the source of protein (Anthony et al. 1997). Coronary artery atherosclerosis extent
was quanti®ed on a subset of monkeys from each treatment group (soya(ÿ), n 18; soya( ),
n 15). Average lesion size in the soya( ) group was approximately 70 % smaller (P 005)
than in the soya(ÿ) group (MS Anthony, TB Clarkson and TB Bullock, unpublished results).
These data would suggest that the alcohol-extractable material, probably the phyto-oestrogens,
inhibits atherogenesis.
In another study in surgically postmenopausal cynomolgus monkeys, the effects of
soyabean with its phyto-oestrogens were compared with those of conjugated equine oestrogens
(Premarin1 (Wyeth-Ayerst Laboratories, Philadelphia, PA, USA), the most commonly used
oestrogen-replacement therapy in the USA) on atherosclerosis in the iliac artery (Anthony &
Clarkson, 1998). Animals were randomized into one of three groups: (1) a group fed on a diet
containing iso¯avone-extracted soyabean protein (soya(ÿ), n 56), (2) a group fed on soyabean
protein with the phyto-oestrogens intact (soya( ), n 59), or (3) a group fed on the iso¯avone-
Fig. 6. Effects of phyto-oestrogen-extracted soyabean protein (soya(ÿ), n 56), phyto-oestrogen-
intact soyabean protein (soya( ), n 59) or conjugated equine oestrogens (CEE, Premarin1
(Wyeth-Ayerst Laboratories, Philadelphia, PA, USA), n 63) on atherosclerosis progression in the
common iliac artery of surgically postmenopausal cynomolgus monkeys (Macaca fasicularis).
Data are expressed as the percentage of each group in which atherosclerosis progressed or was
inhibited. Soya( ) v. soya(ÿ), P 003; CEE v. soya(ÿ), P 0007; soya( ) v. CEE, P 062.
Adapted from Anthony & Clarkson (1998).
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extracted soyabean protein with Premarin1 (n 63) added to approximate the usual dose for
women. Atherosclerosis progression in the common iliac artery was evaluated after 3 years of
treatment. Fig. 6 shows the percentage of each group that demonstrated atherosclerosis pro-
gression or inhibition of atherosclerosis progression. These data suggest that both soyabean
phyto-oestrogens and conjugated equine oestrogen inhibit atherosclerotic plaque progression
relative to the phyto-oestrogen-extracted soyabean protein-treated control group, and the effects
of the two treatments are similar.
Kirk et al. (1998) recently evalulated the effects of diets containing either intact or phyto-
oestrogen-extracted soyabean on atherosclerosis in two strains of mice, LDL receptor-de®cient
(LDLr-null) and wild-type (C57BL=6) mice. Among the wild-type mice, lesion area was sig-
ni®cantly smaller in those fed on intact or unextracted soyabean protein compared with phyto-
oestrogen-extracted soyabean protein, but no difference in the extent of atherosclerosis was
seen in the LDL receptor-de®cient mice. The effects on atherosclerosis are similar to those for
plasma and LDL-cholesterol (described earlier), suggesting that iso¯avones modulate plasma
cholesterol concentrations by increasing LDL-receptor activity and thereby inhibiting ather-
ogenesis.
While the data are just now accumulating, soyabean protein containing phyto-oestrogens
appears to protect against atherosclerosis progression. The magnitude of the effect appears to
be comparable to that of traditional postmenopausal oestrogen therapy (Premarin1). The LDL
receptor appears to play a role in modulating the effects of the iso¯avones. These data on the
bene®ts of soyabean protein containing iso¯avones, which reduce the extent of atherosclerosis,
are encouraging for the prospect of reducing the risk of CHD.
Lack of an effect of puri®ed iso¯avones on plasma lipid concentrations
Two recent reports have evaluated the effects of puri®ed phyto-oestrogen pills on cardiovas-
cular disease risk factors. The ®rst was a randomized, placebo-controlled cross-over trial, in
which menopausal and perimenopausal women (n 21) were treated with either puri®ed iso-
¯avone pills containing about 80 mg iso¯avones (45 mg genistein, 34 mg daidzein, 3 mg gly-
citin) or a placebo for 5-week periods (Nestel et al. 1997). These investigators found improved
systemic arterial compliance with iso¯avone pill treatment, but no effect on plasma lipids. The
second half of the cross-over was extended to a 10-week period to see if additional treatment
time was required for plasma lipid effects, but there continued to be no effect of puri®ed
iso¯avones on the plasma lipid concentrations. In a second randomized, placebo-controlled,
double-blind trial, forty-six men and thirteen postmenopausal women were treated with puri®ed
phyto-oestrogen pills containing 55 mg iso¯avones (16 mg biochanin A, 30 mg genistein, 8 mg
formononetin, 1 mg daidzein) isolated from subterranean clover, for 8 weeks (Hodgson et al.
1998). No effect of the puri®ed phyto-oestrogen pills was found on plasma lipid and lipoprotein
concentrations.
In considering these studies together with the two previously cited human studies (Baum et
al. 1998; Crouse et al. 1998), one of the differences is that where no cholesterol-lowering effect
of the phyto-oestrogens was shown, the subjects were not selected to be hypercholesterolaemic.
Thus Crouse et al. (1998) reported no signi®cant effect on total cholesterol or LDL-cholesterol
with the soyabean protein supplements in the half of the subjects with LDL-cholesterol con-
centrations below the median at baseline. Other possible explanations for a lack of effect of
puri®ed iso¯avones include: (1) the phyto-oestrogens are not the active agent: it is some other
unidenti®ed component that is removed with alcohol extraction and is present in soyabean in
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concentrations parallel to the phyto-oestrogens; (2) the phyto-oestrogens are inactivated when
they are isolated and puri®ed and (3) an enabling factor in soyabean protein allows the phyto-
oestrogens to have the bene®cial effects on plasma lipids and lipoproteins.
Discussion
Considerable evidence exists that soyabean with its phyto-oestrogens has a bene®cial effect on
cardiovascular disease, preventing the progression of atherosclerosis by interaction with mul-
tiple biological processes. A large part of this bene®t appears to be mediated by effects on
plasma lipid and lipoprotein concentrations. Soyabean phyto-oestrogens, and genistein in
particular, also impact bene®cially on vascular reactivity. Another potential bene®t of soyabean
phyto-oestrogens, which has been shown in vitro, is prevention of lipoprotein oxidation
(Hodgson
et al. 1996; Ruiz-Larrea et al. 1997). The resulting decrease in oxidized LDL particles, which
are considered more atherogenic (Witztum & Steinberg, 1991), may decrease the risk of
atherosclerosis. The phyto-oestrogens in soyabean protein may also have some direct effects on
the artery wall and the cells involved in promotion and progression of atherosclerosis. Genistein
has been shown, in vitro, to inhibit the migration and proliferation of smooth muscle cells
(Fujio et al. 1993; Shimokado et al. 1994, 1995), to inhibit platelet activation (Kuruvilla et al.
1993; Murphy et al. 1993) and aggregation (Asahi et al. 1992; McNicol, 1993), and to reduce
platelet serotonin uptake (Helmeste & Tang, 1995). Each of these effects of genistein may
delay the development of atherogenesis.
It remains to be shown that an intervention incorporating soyabean with its phyto-
oestrogens into a western-type diet can favorably impact cardiovascular disease morbidity and
mortality (e.g. stroke, myocardial infarction). Questions remain regarding dose and form of the
phyto-oestrogens to maximize the bene®ts and minimize any potential risks. Incorporation of
soyabean with its phyto-oestrogens into a western diet, however, may prove to be an important
means for prevention of cardiovascular disease and may have additional bene®ts for other
chronic diseases.
Areas for further investigation
Several gaps in our knowledge of phyto-oestrogens remains to be investigated if these mole-
cules are to be considered as a preventive therapy for cardiovascular disease:
(1) The appropriate dose of phyto-oestrogens required for cardiovascular bene®t is uncertain.
(2) The relative potency of each of the two principal phyto-oestrogens in soyabean, genistein
and daidzein, of the much less abundant glycitin, and of the metabolites (e.g. equol,
O-desmethylangolensin, dihydrodaidzein, 4-ethylphenol) needs to be determined and
compared with parent compounds. Whether some optimum ratio of the phyto-oestrogens
exists should also be determined.
(3) The question remains why puri®ed iso¯avone preparations appear to have no effect on
plasma lipid and lipoprotein concentrations, although step-wise reductions in LDL-
cholesterol levels occur with increasing doses of iso¯avones administered in soyabean
protein.
(4) For soyabean phyto-oestrogens to be considered for primary prevention of cardiovascular
disease, their safety in other organ systems must be established.
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Effects of phyto-oestrogens on skeletal tissues
The published data supporting a bene®cial effect of phyto-oestrogens on bone mass are limited,
but reports have been rather consistent in support of positive bone effects of iso¯avones and
other phyto-oestrogens in human subjects, most experimental animal models, and bone
explants or bone cells in vitro. An increase in bone mass could result from either increased bone
formation by osteoblasts or decreased bone resorption by osteoclasts, and would thus help to
prevent the development of osteoporosis. Although the cellular mechanism of action of phyto-
oestrogens on bone may involve either osteoblasts or osteoclasts, OR are present in relatively
low numbers in osteoblasts while mammalian osteoclasts are not believed to express these
receptors. Thus, a genomic effect of phyto-oestrogens, consistent with their ability to interact
with the ligand-binding portion of the OR in vitro, may underlie a direct effect of these
molecules on osteoblasts, while other responses of osteoblasts or osteoclasts may result from
either indirect mechanisms or non-genomic actions (see later).
Investigations of phyto-oestrogen effects on bone in human subjects
In human subjects, phyto-oestrogen molecules may bene®t bone mass by direct effects via bone
cells; however, the consumption of soyabeans or soyabean protein, as an extract or hydrolysate,
apparently has a conservatory effect on Ca. In contrast to the animal protein lactalbumin (a
milk protein), isolated soyabean protein, which contains iso¯avones, exerts a modest decrease
in urinary Ca excretion during both the postprandial and 24 h periods (Anderson et al. 1987). In
addition, the consumption of soyabean protein stimulates glucagon during the postprandial
period at a much greater rate than lactalbumin. Based on the results of this study, however, it
may have been the iso¯avones that exerted the favorable effect on Ca retention following
soyabean consumption. Whatever the acute mechanism of soyabean protein (containing iso-
¯avones) on Ca conservation is, it is highly signi®cant, and it may help to offset lower Ca
intakes among vegetarians and counter other potentially adverse dietary factors in the diets of
vegans (Anderson & Miller, 1998).
Post-menopausal women in general may bene®t from dietary supplementation with iso-
¯avone-enriched soyabean products to maintain bone mass. A report (Potter et al. 1998) of
soyabean supplementation of sixty-six postmenopausal women compared bone measurements
at baseline and 6 months after feeding a soyabean-protein supplement enriched in genistein and
daidzein (doses of approximately 56 and 90 mg of iso¯avones=d), compared with treatment
with a casein=non-fat dry milk supplement (no iso¯avones). The higher dose resulted in sig-
ni®cant improvements (P< 005) in both bone mineral density and content of lumbar vertebrae
relative to the control group, with no signi®cant bene®t in subjects receiving the lower dose.
These ®ndings, which illustrate the positive responses of vertebral bone mineral density of the
postmenopausal women in the study, suggest that a threshold dose exists for any bene®t of
iso¯avones on bone mineral density. Longer prospective studies examining the effects of
phyto-oestrogens on bone parameters of postmenopausal women are needed to clarify effective
doses and whether other skeletal sites will also bene®t from iso¯avones over a longer time
frame of treatment.
Some evidence is also available that consumption of soyabean proteins can reduce urinary
markers of bone resportion. Pansini et al. (1997) reported that non-osteoporotic, post-
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menopausal women who consumed 60 g isolated soyabean proteins daily for 3 months had
signi®cant reductions in both deoxypyridinoline and N-telopeptide excretion.
In addition to the limited data on effectiveness of naturally-occurring iso¯avones in pre-
venting bone loss in postmenopausal women, the bone-conserving effects of chronic treatment
with ipri¯avone, a synthetic iso¯avone, in women with low bone mass have been reported.
Gennari et al. (1997) studied 453 postmenopausal women in a double-blind, placebo-con-
trolled, 2-year study with random assignment of women to either ipri¯avone (200 mg three
times per day) or placebo; all women received 1 g Ca=d orally. The ®nal outcome showed a
signi®cant (P< 005) difference between the placebo groups, which lost 16 % at one study
centre and 35 % of bone mass at the second centre, and the ipri¯avone group, which main-
tained bone mass (approximately 0 % loss).
Data on the effectiveness of phyto-oestrogens in promoting bone accretion and bone
retention in young adult women are also needed in addition to longer trials with these dietary
molecules in older women. An increase in peak bone mineral density of young women may
possibly delay or prevent development of osteoporosis in later life. Crucial data are required
from longer human trials with iso¯avones establishing the long-term bene®ts of these non-
steroidal molecules.
Animal model experiments of phyto-oestrogen effects on bone
Some of the limited number of published reports on the skeletal effects of phyto-oestrogens on
animals are highlighted here.
Rodent studies. The most commonly used animal model for examining the effect of
molecules with the potential for anti-osteoporotic actions has been the ovariectomized (OVX)
rat. Three different studies have been reported in which OVX rats have been treated with either
soyabean with its naturally-occurring iso¯avones, a genistein-rich soyabean iso¯avone pre-
paration, or puri®ed genistein. Feeding an iso¯avone-containing soyabean protein-based diet to
OVX rats resulted in retention of signi®cantly more bone than feeding a casein-based diet
(Arjmandi et al. 1996). Similarly, OVX lactating rats treated with a genistein-rich soyabean
iso¯avone preparation for 14 d retained signi®cantly more bone mass than vehicle-treated
controls (Anderson et al. 1995a; JJB Anderson, WW Ambrose and SC Garner, unpublished
results). Puri®ed genistein also promoted a similar improvement in femur bone mass of OVX
rats (Blair et al. 1996). The common factor among these three studies was the presence of
iso¯avones, including genistein. The studies by Anderson et al. (1995a; JJB Anderson, WW
Ambrose and SC Garner, unpublished results) found that soyabean iso¯avones had an apparent
biphasic effect on bone retention. A similar biphasic response in which lower doses had sig-
ni®cant effects on bone while higher doses produced less bene®t has been reported for bone-
derived cells in culture as discussed later. Further studies of the effects of phyto-oestrogen
molecules over a broad dose range are needed to determine whether a potentially narrow range
exists for bene®cial effects of phyto-oestrogens as suggested by these ®ndings of a biphasic
relationship.
The research reported above involved the iso¯avones found in soyabean products. These
molecules have been studied most frequently because soyabean is the most common source of
phyto-oestrogens in the human diet. However, the human diet also includes many legumes,
such as lima beans (Phaseolus limensis), pinto beans (Phaseolus vulgaris), and sprouts of
clover (genus Trifolium) or lucerne seeds (Medicago sativa) (Franke et al. 1994), that contain
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signi®cant amounts of another phyto-oestrogen, coumestrol (Table 1). Dodge et al. (1996)
found signi®cant effects of coumestrol but not of genistein, on prevention of bone loss in rats
after ovariectomy. Coumestrol administered orally appeared to be equally effective compared
with ethinyl oestradiol in preventing bone loss, but doses at least 100-times higher were
required. In another study, injection of coumestrol to OVX rats twice per week has been
reported to cause a similar signi®cant improvement in femur bone mass to that shown with
oestradiol (Draper et al. 1997). Interestingly, the same report contained results of an experiment
in which dietary supplementation with an iso¯avone-containing extract from subterranean
clover did not signi®cantly improve the bone mass of OVX rats. A similar ®nding was obtained
by JJB Anderson, WW Ambrose and SC Garner (unpublished results) for young, growing OVX
rats, which had modest, but not signi®cant, gains in femur bone mass after 4 weeks of treatment
with a genistein-rich soyabean iso¯avone extract.
Signi®cant bone retentive effects of the synthetic iso¯avone, ipri¯avone, have also been
reported. Cecchini et al. (1997) found that either 400 mg=kg body weight of ipri¯avone mixed
in the food of OVX rats or subcutaneous injection of 272 g=kg of 17b-oestradiol per day could
decrease bone resorption to values of sham-operated animals. Although ipri¯avone produced
similar bone effects to that of oestradiol, no signi®cant uterotrophic effect was observed.
Non-human primate studies. Although clearly valuable, relatively few primate studies of
the effects of phyto-oestrogens on bone mass have been published and positive effects of
iso¯avones on retention of bone after ovariectomy in non-human primates have been dif®cult to
demonstrate. One prospective study in which primates were treated with a single dose of
iso¯avones (28 mg per animal) for 2 years has been published (Jayo et al. 1996). No positive
effects of the iso¯avones on bone measurements were reported. The investigators suggested
that the lack of signi®cant improvement in bone mass in this experiment could have resulted
from the use of a single dose of iso¯avones, which may have been too small to produce a
positive effect on bone mass or that the Ca level in the diet (equivalent to a human intake of
about 800 mg=d) was too low. Additional research has been reported by the same group
(Register et al. 1997) in which they fed OVX macaques (genus Macaca) for 6 months on either
casein=lactalbumin or soyabean protein diets with and without oestrogen. Serum Ca was sig-
ni®cantly increased in the soyabean protein-fed groups compared with the casein=
lactalbumin groups, which is consistent with the ®nding of Anderson et al. (1987) that soya-
bean protein could conserve Ca in humans.
An additional study in OVX cynomolgus monkeys examined the rate of bone formation in
cortical bone (Lees & Ginn, 1998). All animals were OVX, and bone was collected 7 months
after feeding on either casein or soyabean-based diets with and without treatment with oes-
tradiol. While oestradiol signi®cantly reduced bone formation rates at periosteal, osteonal, and
endocortical surfaces, the only statistically signi®cant effect of the soyabean diet was an
increase in bone formation at the endocortical surface. The authors conclude that phyto-oes-
trogens in the dietary soyabean isolate are effective in improving cardiovascular risk factors but
not bone under the same conditions.
The dif®culty of demonstrating positive effects of iso¯avones on retention of bone after
ovariectomy may be consistent with the concept that the dose of iso¯avones necessary to
demonstrate gains in bone tissue is relatively high, about 90 mg=d. This requirement is con-
gruent with studies using rodent models. Also the animal experimental results suggest that a
threshold dose of iso¯avones needs to be consumed for a lengthy period of time, i.e. months to
years, before any measurable effect on bone can be observed. Doses higher than the threshold
appear to be no more bene®cial than the minimal effective dose; very high doses are less
effective, and if too high, they may even be toxic.
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In vitro bone cell studies of phyto-oestrogens
The use of bone tissue or osteoblast-like and osteoclast-like cells in culture have provided
important information about the effects of phyto-oestrogen molecules on bone activity.
Bone tissue in organ culture. A single published study has examined the effects of phyto-
oestrogens on bone tissues in organ culture. Tsutsumi (1995) reported that coumestrol inhibited
bone resoption and stimulated bone mineralization in 9-d-old chick embryonic femur explants.
In addition, the increased bone resorption resulting from treatment with parathyroid hormone,
the hormonal form of vitamin D, or prostaglandin E2 could be inhibited by coumestrol or 17b-
oestradiol. The author reported that the optimal effects were obtained with approximately
10ÿ5 M-coumestrol, which is about 100±1000-fold higher than the optimal concentration of
oestradiol (Miksicek, 1994).
Osteoblast-like cells. Studies of osteoblast-like cells in culture have shown that they
respond to phyto-oestrogens. Different cell lines with osteoblast-like properties have been
examined in vitro to con®rm and extend the research on effects of phyto-oestrogens on bone in
vivo. An important ®nding from at least two laboratories has been the biphasic response of
osteoblast-like cells to a wide range of concentrations of phyto-oestrogens (Benvenuti et al.
1991; Anderson & Garner, 1997).
Benvenuti et al. (1991) tested the effects of ipri¯avone, a synthetic ¯avone molecule with a
structure closely related to the iso¯avones, on bone cells in vitro. They found the alkaline
phosphatase (EC 3.1.3.1) activity of UMR-106 osteoblast-like cells responded to increasing
doses of ipri¯avone with a biphasic response (Fig. 7). The peak activity of alkaline phosphatase
of approximately three times that of the baseline for control cells was found at 10ÿ10 M-
ipri¯avone.
The effects of genistein and 17b-oestradiol on alkaline phosphatase activity have also been
examined in the ROS-SMER-14 osteoblast-like cell line (Fig. 8) (T Ohue, SC Garner and JJB
Anderson, unpublished results). It was found that both the ROS-SMER-14 and its parent ROS
17=28 cell lines responded with modest increases in alkaline phosphatase activity. Although
the ROS.SMER-14 cells express approximately eight times as many oestrogen receptors as the
ROS 17=28 cells (Migliaccio et al. 1992), the responses of alkaline phosphatase to addition of
Fig. 7. Ipri¯avone, a synthetic iso¯avone, exerts a biphasic effect on alkaline phosphatase (EC
3.1.3.1) activity in UMR-106 osteoblast-like cell line (adapted from Benvenuti et al. 1991). Vertical
lines represent SE.
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genistein (10ÿ10±10ÿ8 M) were similar in both cell lines, suggesting that other mechanisms of
action of phyto-oestrogens may be operating in these cells. At higher (10ÿ6±10ÿ4 M) con-
centrations of genistein and 17b-oestradiol both ROS.SMER-14 and ROS 17=28 cells assumed
a more rounded appearance with reduced contacts with other cells and the culture plate. The
presence of DNA ladders after gel electrophoresis suggests that this an apoptotic rather than a
toxic effect (JJB Anderson, T Ohue and SC Garner, unpublished results). The differential
effects of genistein and 17b-oestradiol on alkaline phosphatase and cell morphology suggest
that some effects of these molecules may be through similar mechanisms of action, while some
bone-related effects may involve non-oestrogenic actions of genistein or other phyto-oestro-
gens. A closely related phyto-oestrogen, daidzein, did not produce a biphasic response in the
same osteoblast-like cells (T Ohue, SC Garner and JJB Anderson, unpublished results).
Studies of osteoblast-like cells in culture demonstrate that these cells respond to phyto-
oestrogens and related molecules. Comparison of the effects of iso¯avones and chemically
similar molecules, however, demonstrates that various cell lines may respond differently to
phyto-oestrogens. Further, the responses of bone cells in vivo may be different from those
observed in vitro, and it is likely that our knowledge of the mechanisms of action of phyto-
oestrogens on osteoblasts will continue to unfold in the next few years.
Osteoclast-like cells. Inhibition of osteoclastic cell activity in vivo by oestrogens, and
possibly phyto-oestrogens, is believed to be mediated via osteoblasts since mammalian
osteoclasts are generally considered not to express oestrogen receptors. Despite this postulated
relationship in vivo, however, direct inhibitory effects of phyto-oestrogens have been demon-
strated on avian osteoclasts in vitro by Blair et al. (1996). They found that genistein, but not the
structurally similar molecule daidzein, could exert this effect. Both Blair et al. (1996) and
Williams et al. (1998) proposed that iso¯avones inhibited activities of osteoclast-like cells by
interfering with speci®c enzymatic systems, such as the tyrosine kinase (EC 2.7.1.112) activity
of epidermal growth factor receptor protein, i.e. a non-genomic mechanism. Tobe et al. (1997)
assayed parathyroid hormone-stimulated bone resorption by mixed cultures of mouse bone cells
on dentine slices in vitro. The number of resorption pits was inhibited by calcitonin and sig-
ni®cantly stimulated by daidzein but not genistein or ipri¯avone. Further research will be
required to resolve these reports of divergent actions of phyto-oestrogens on osteoclasts in
vitro.
Fig. 8. Alkaline phosphatase (EC 3.1.3.1) activity is signi®cantly increased by both genistein (s)
and 17a-oestradiol (d) in ROS.SMER-14 osteoblastic cells (T Ohue, SC Garner and JJB
Anderson, unpublished results).
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Summary. Taken together these studies suggest that iso¯avones, and possibly other phyto-
oestrogens, may operate by both oestrogen-receptor-mediated pathways and by pathways that
involve so-called non-genomic mechanisms that could involve both the putative cell-surface
oestrogen receptor and enzymatic pathways such as tyrosine kinase (see later). Isolated bone
cells and cell lines will continue to provide valuable models for future studies of the effects of
the many non-steroidal oestrogen-like molecules on the health bene®ts of soyabean-derived
iso¯avones and other phyto-oestrogens.
Mechanisms of action of phyto-oestrogens on osteoblasts and osteoclasts
Phyto-oestrogens, like oestrogens, are thought to interact at the cellular level by two major
mechanisms: genomic and non-genomic.
Interactions of phyto-oestrogens with the oestrogen receptor. The oestrogen receptor is
believed to act primarily through altering the production of speci®c proteins within the cell by
binding to regulatory sites on DNA molecules (oestrogen response elements (ORE)) and
increasing or decreasing expression of speci®c genes. Depending on the af®nity of the phyto-
oestrogen molecule for the OR, binding of a phyto-oestrogen to the receptor may result in
partial activation of the receptor (weak agonistic effect) or displacement of an oestrogen
molecule, which may reduce receptor activation (antagonistic or anti-oestrogenic effect).
Phyto-oestrogens combine with the OR but at lower af®nities than 17b-oestradiol. The
af®nities of selected phyto-oestrogens for the oestrogen receptor in comparison to 17b-oes-
tradiol are listed in Table 2. Miksicek (1993) has demonstrated that diverse naturally occurring
and synthetic molecules can activate human nuclear oestrogen receptors in an in vitro reporter
assay. Although the non-steroidal oestrogens are less potent than 17b-oestradiol, they do
generate the same maximal response when the dose tested is high enough. These ®ndings
suggest that the cumulative effect of the many molecules of plant origin with weak agonism
may be a signi®cant factor in human health, including the maintenance of bone mass.
Nearly all cell types are believed to be affected by oestrogens in some way because OR are
present in almost all mammalian cells that have nuclei, with the possible exception of osteo-
clasts. The response of different cells may depend in large part, therefore, on the number of OR,
which may be approximately 100±1000 times higher in reproductive tissues than in most other
cells of the body, including bone cells. Migliaccio et al. (1992) reported that oestrogens could
activate oestrogen receptors present in both the wild type ROS 17=2.8 cells and in the
ROS.SMER-14 cells stably transfected with mouse uterine OR.
The genomic effects of oestrogens are believed to be mediated via an intracellular oes-
trogen receptor that activates gene transcription by interacting with ORE. A second intra-
cellular OR molecule has recently been discovered (Kuiper et al. 1996). The classical OR is
now designated OR-a and the more recently discovered, structurally similar, protein has been
named OR-b. Initial reports suggest that the phyto-oestrogens, genistein and coumestrol, have a
signi®cantly higher af®nity for OR-b than for OR-a (Kuiper et al. 1997).
Both OR-a and OR-b are expressed in bone cells (Arts et al. 1997; Onoe et al. 1997).
Recently published reports indicate that the expression of OR-a and=or OR-b may vary during
differentiation of osteoblasts in vitro. The pattern of expression, however, may be dependent on
the particular cells being studied. While Onoe et al. (1997) found that primary cultures of rat
osteoblasts expressed OR-b at a relatively constant level during 28 d in culture, the expression
of OR-a increased by 7±8-fold in parallel with osteoblastic differentiation. Bodine et al. (1998)
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also examined OR-a expression in primary rat osteoblasts. They found a 70-fold increase in
OR-a mRNA levels by days 22±25 of culture. In contrast, Arts et al. (1997) found that a human
osteoblastic cell line (SV-HFO) had approximately 10-fold higher levels of OR-b mRNA
expression in mineralizing (day 21) cells v. proliferating (day 6) cells, but OR-a mRNA
increased only approximately 2-fold.
OR-a and OR-b can form heterodimers (Cowley et al. 1997; Pettersson et al. 1997) and,
thus, the responsiveness of cells may differ depending on the relative expression of the two
receptor subtypes. Paech et al. (1997) examined the differential ligand activation of OR-a and
OR-b with an ORE reporter construct and with an AP-1 reporter construct. Although oestradiol
and a panel of ligands, including tamoxifen and raloxifene, had almost the same activation
pro®le with the ORE reporter construct with both OR, the responses of the AP-1 reporter
construct were distinctly different. Oestrogen activated the AP-1 reporter construct in the
presence of OR-a but not OR-b, while tamoxifen was a potent activator of both OR-a and OR-
b. The next few years promise to be an exciting period of research into the role of these two
oestrogen receptor subtypes in explaining some of the differential effects of oestrogenic
compounds, including phyto-oestrogens, on bone cells compared with reproductive tissues.
Non-genomic mechanisms. Phyto-oestrogens may interact with other cellular proteins in
addition to the classical oestrogen receptor. The existence of membrane-bound receptor for
oestrogenic molecules has been proposed (Watson et al. 1995). In addition, genistein has been
demonstrated to inhibit tyrosine kinase (Akiyama et al. 1987) and topoisomerase II (EC
5.99.1.3) (Okura et al. 1988). An important function of the phyto-oestrogens in plant cells is as
antioxidants, and it is likely that they could perform the same function in animal cells. Proposed
actions of phyto-oestrogens through non-genomic mechanisms are supported by the direct
action of phyto-oestrogens on osteoclasts (Williams et al. 1998), which appear to lack oes-
trogen receptors. The major effect of phyto-oestrogens on osteoclasts may still be mediated via
osteoblasts however, since secretion of cytokines by osteoblastic cells is believed to be the
major mechanism for regulation of osteoclastic activity in response to calcaemic hormones and
oestrogen.
The potential mechanisms by which phyto-oestrogens may affect cellular activities are
illustrated in Figs. 4 and 5. The mechanisms of action are divided into the genomic and non-
genomic effects of phyto-oestrogens. The genomic effect involves OR and activation of the
ORE, whereas non-genomic actions involve membrane receptors and cytosolic enzymes.
Discussion
These more recent investigations of the oestrogenic activities of the iso¯avones, either as
partial oestrogen agonists or anti-oestrogens (inhibitors of natural oestrogen activity), are
clearly relevant to bone health and disease. Soyabean iso¯avones, mainly genistein and daid-
zein, have now been shown by at least four different laboratories to conserve bone in OVX-
rodent models. They probably have similar bone conservatory effects in higher mammalian
species. The phyto-oestrogen coumestrol, which is not commonly consumed by humans, may
be more potent than the soyabean iso¯avones in preserving bone mass. Clearly the application
of phyto-oestrogens for the prevention and treatment of osteoporosis is approaching.
These published reports support the concept that a threshold dose of iso¯avones needs to
be consumed for a suf®ciently long period of time, i.e. months to years depending on the
species, before any measurable effects on bone mass and density can be observed. A further
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complexity appears to be that consumption of higher doses does not convey further bene®t of
iso¯avones, with higher doses possibly being less effective. Although it is possible that
extremely high doses may even have adverse effects, such events are not likely from food
sources alone. However, the increasing availability of iso¯avone-enriched food supplements
and puri®ed phyto-oestrogens in capsule form should be viewed with caution because of our
current lack of knowledge of the potential toxicity of these molecules. Greater information
from human studies currently in progress, however, is needed before the ef®cacy of these
preparations in human subjects is known. The use of soyabeans and their products make this
approach, as opposed to drug formulations that preserve bone, more attractive to many post-
menopausal women.
The consumption of practically any soyabean product means that iso¯avones will also be
consumed from these foods in amounts that depend on the degree of processing (see Fig. 1).
The doses of phyto-oestrogens that are effective in in vitro studies are approximately 10ÿ8 M,
but these concentrations are dif®cult to translate to either animal models or human studies.
Nevertheless, the only positive effects of phyto-oestrogens on bone observed so far in post-
menopausal women have been small and limited to the lumbar vertebrae. Although data have
not yet been published from several human studies in progress, additional evidence for skeletal
bene®ts of soyabean iso¯avones is anticipated in the next few years. It may also be necessary to
accumulate data from studies lasting decades to assess the effects of lifelong intakes of
soyabean products at levels similar to those of high-consuming Asian populations.
Soyabean intake and cancer risk
Within the past few years soyabean foods and certain soyabean components have attracted
considerable research attention for their potential role in cancer prevention and treatment. A
critical early development in this ®eld was the conclusions of a workshop by the National
Cancer Institute, USA, in 1990 which led to the Institute allocating signi®cant funds toward
investigating the anticancer potential of soyabean components (Messina & Barnes, 1991).
Understandably, initial interest in the anticancer effects of soyabean focused primarily on
breast cancer. Early enthusiasm for this relationship was based largely on three primary
observations: (1) the low breast cancer mortality rates in Asian, soyabean food-consuming
countries; (2) animal work showing that soyabean inhibits chemically induced mammary
carcinogenesis (Barnes et al. 1990); and (3) the potential anti-oestrogenic effects of soyabean
iso¯avones.
A comprehensive review by Messina et al. (1994) noted that the evidence supporting the
potential anticancer effects of soyabean, although far from conclusive, was by no means limited
to breast cancer. Published data suggest that soyabean may reduce the risk of a variety of
cancers and, in particular, cancer of the prostate. Consequently, this section on cancer focuses
primarily on breast and prostate cancer, and in particular the potential anticarcinogenic effects
of the soyabean iso¯avones. Although several different putative anticarcinogens have been
identi®ed in soyabeans, including phenolic acids (Ramakrishna et al. 1989), phytosterols (Rao
& Janezic, 1992), protease inhibitors (Bowman Birk Inhibitor and Kunitz inhibitor; Kennedy &
Manzone, 1995), inositol hexaphosphate (Graf & Eaton, 1993), saponins (Koratkar & Rao,
1997), and melanoidins (miso) (Kamei et al. 1997), the evidence most strongly supports a role
for the iso¯avones in the hypothesized anticancer effects of soyabean.
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Iso¯avones as anticarcinogens
As noted previously, three primary aglycone iso¯avones are present in soyabeans: genistein,
daidzein and glycitein. Glycitein is present in relatively small amounts and little is known about
its biological activity, although it has been shown to be a weak oestrogen (Sonn et al. 1997).
The iso¯avone daidzein has exhibited anticancer effects both in vitro (Hirano et al. 1989;
Higashi & Ogawara, 1994) and in animal models (Jing et al. 1993); however, the greatest focus
has been on genistein. Recently, the Chemopreventive Branch of the Division of Cancer
Prevention and Control, National Cancer Institute, National Institute of Health in the United
States published its clinical development plan for genistein (Chemopreventive Branch and
Agent Development Committee, 1996).
Literally hundreds of in vitro studies show that genistein can inhibit the growth of a wide
range of both hormone-dependent and hormone-independent cancer cells with an IC50 of
between approximately 56 10ÿ6 and 10ÿ4 M (approximately 2±25 mg=ml). Genistein has been
shown to be effective in inhibiting growth of breast cancer cell types and many others (Table
3). In addition, genistein has been shown to inhibit the metastatic activity in vitro of both breast
(Scholar & Toewa, 1994) and prostate cancer cells (SantibaÂnÄez, 1997), independent of effects
on cell growth.
In a variety of cell lines, including cells derived from human gastric cancer (Yanagihara,
1993), oestrogen-receptor positive and negative human breast carcinoma cell lines (Shao et al.
1998), leukaemic cells (Spinozzi, 1994), melanoma cells (Rauth et al. 1997), and colon cancer
cells (Kuo, 1996), genistein arrested cell cycle progression at G2-M. These studies also showed
that the addition of genistein to cancer cells induces differentiation and apoptosis.
The precise mechanism(s) by which genistein inhibits the growth of cancer cells has not been
identi®ed, but several have been proposed. Although the antioxidant properties of geni-stein (Wei
et al. 1993) may contribute to the anticancer effects observed in vitro, it is more likely that these
effects result from the ability of this iso¯avone to modulate multiple processes associated with
neoplastic transformation (Table 4). In addition to these effects, Peterson et al. (1996) reported that
genistein increased the in vitro concentration of transforming growth factor beta.
Soyabean intake and breast cancer
As noted earlier, in addition to the low breast cancer mortality rates in Asian countries, much of
the enthusiasm for the anticancer effects of soyabean foods was because weak oestrogens,
Table 3. Selected cancer cell types inhibited by genistein in vitro
Cell type Reference
Breast cancer Peterson & Barnes, 1991, 1996
Pagliacci et al. 1994
Prostate cancer Peterson & Barnes, 1993
Naik et al. 1994
Kyle et al. 1997
Melanoma Rauth et al. 1997
Leukaemia Makishima et al. 1993
Gastric cancer Matsukawa et al. 1993
Colon cancer Kuo, 1996
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including iso¯avones, have been posulated to function as anti-oestrogens in vivo (Geynet et al.
1972; Martin et al. 1978). On a molar basis, relative to physiological oestrogens, iso¯avones
are quite weak, possessing between 16 10ÿ4 and 16 10ÿ3 the activity of 17b-oestradiol
(Folman & Pope, 1966; Mayr et al. 1992; Markiewicz et al. 1993). Although data are con-
¯icting on this point, limited support exists for the notion that iso¯avones are anti-oestrogenic.
In fact, more than 30 years ago Folman & Pope (1966) demonstrated in female mice that
subcutaneous injection of genistein inhibited oestrone-stimulated increases in uterine weight.
More recently, genistein (Wang et al. 1996) and equol (Sathyamoorthy & Wang, 1997) were
shown to inhibit oestradiol-stimulated pS2 mRNA expression in MCF-7 cells. In addition,
genistein, daidzein and equol were found to down-regulate oestrogen receptor mRNA
expression.
The prevailing hypothesis has been that iso¯avones exert anti-oestrogenic effects when
placed in a high oestrogen environment, such as exists in premenopausal women, and oes-
trogenic effects in a low oestrogen environment, such as in postmenopausal women. This
hypothesis has some support; for example, MaÈkelaÈ et al. (1995) found that soyabean con-
sumption led to an increase in uterine weight in OVX mice not given the synthetic oestrogen
diethylstilbestrol, but to a decrease in uterine weight in mice given diethylstilbestrol (Fig. 9).
Also, Foth & Cline (1998) found that soyabean-feeding partially antagonized the stimulatory
effect of oestrogen on endometrial and breast cancer tissue in OVX macaques, although
soyabean had slight stimulatory effects on proliferation in the breast tissue of animals not given
oestrogen.
Another potentially important observation related to the anti-oestrogenic hypothesis was
reported by Cassidy et al. (1994, 1995), who found that premenopausal women consuming 60 g
textured soyabean product (containing 45 mg iso¯avones) experienced a 2.5 d increase in the
length of their follicular phase, whereas no change was noted in women fed on a similar amount
of soyabean from which the iso¯avones had been chemically removed (Cassidy et al. 1995).
Particularly noteworthy is the ®nding that serum follicle stimulating hormone and luteinizing
hormone levels decreased signi®cantly in response to the consumption of soyabean iso¯avones.
Findings that soyabean increases follicular phase length may be quite relevant to the
soyabean±breast cancer hypothesis because some data indicate that longer cycles, which are
typical of Asian women, are associated with a reduced risk of breast cancer (Olsson et al. 1983;
Yuan et al. 1988). However, Wu & Pike (1995) have pointed out that in the studies by Cassidy
et al. (1994, 1995), serum oestrogen levels were not decreased, whereas serum oestrogen levels
are typically lower in Asian compared with western women. In contrast to Cassidy et al. (1994,
1995) however, Lu et al. (1996a) observed an increase in menstrual cycle length in response to
soyabean consumption and a decrease in serum oestrogen levels. The difference between the
studies is perhaps a result of the much higher iso¯avone intake in the latter study. To com-
plicate this issue further, however, two recent studies failed to ®nd an effect of soyabean on
menstrual cycle length or oestrogen levels (Duncan et al. 1998; Haggins et al. 1998).
Table 4. Multiple processes associated with neoplastic transformation that may be modulated
by genistein
Protein target of genistein Reference
Tyrosine-speci®c protein kinase Akiyama et al. 1987
Mitogen-activated protein (MAP) kinases Thorburn & Thorburn, 1994
DNA topoisomerase II (EC 5.99.1.3) Constantinou et al. 1990
Epidermal growth factor-induced phosphatidylinositol turnover Imoto et al. 1988
S6 kinase activation Linassier et al. 1990
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Although some evidence suggests that iso¯avones are anti-oestrogenic under some con-
ditions, other research supports a primarily oestrogenic effect of iso¯avones (MaÈkelaÈ et al.
1994; Dees et al. 1997; Santell et al. 1997; Zava & Duwe, 1997). Importantly, genistein has a
biphasic effect on oestrogen receptor-positive breast cancer cell growth in vitro; at micromolar
concentrations growth inhibition occurs, whereas modest growth stimulation occurs at lower
concentrations. The lower concentrations, however, may more accurately re¯ect those likely to
occur in vivo (Zava & Duwe, 1997). Consistent with these ®ndings is work by Santell et al.
(1997), who found that genistein increased uterine weight in OVX Sprague-Dawley rats
without inhibiting the increase in uterine weight caused by oestradiol administration.
Finally, two studies involving premenopausal women concluded that soyabean exerts
oestrogenic effects on breast tissue. In one, nipple aspirates of secreted breast ¯uids, which
have been shown to be an indicator of breast cancer risk by Wrensch et al. (1991), increased in
response to soyabean consumption over a 4-month period, as did the number of atypical cells in
the breast ¯uid (Petrakis et al. 1996). In the other study, McMichael-Phillips et al. (1996) found
that the rate of DNA synthesis by breast cells taken from biopsies of normal breast tissue from
women with benign or malignant breast disease was enhanced by 2 weeks of soyabean feeding.
Although increased cell proliferation has traditionally been regarded as a factor increasing
cancer risk, recent work with the non-steroidal anti-in¯ammatory drug, sulindac, calls this
notion into question. Sulindac increases colon cell proliferation in mice but decreases chemi-
cally-induced colon tumours (Moorghen et al. 1998). In the case of soyabean, perhaps the
increase in cell proliferation is a compensatory response to an increase in apoptosis, as high
doses of genistein have been shown to induce apoptosis in vitro (Shao et al. 1998).
Fig. 9. Relative uterine weight of mice fed on a soyabean-containing or soyabean-free diet with
or without diethylstilbestrol (DES). Outbred Han-NMRI mice were fed on either an Ewos R3 diet
that contained roasted soyabean meal (70 g=kg diet) ( ) or the equivalent soyabean-free non-
puri®ed diet (Ewos R403) in which casein was substituted for soyabean meal ( ). Diets were with
(6mg=kg) or without DES. The uterine weight of animals fed on soyabean without DES (n 32) was
signi®cantly higher than the uterine weight (n 33) of animals not fed on soyabean. The uterine
weight of the animals (n 18) fed on soyabean and DES was signi®cantly lower than the uterine
weight of animals (n 22) fed on DES but not on soyabean. Statistical signi®cance (two-way
ANOVA) of effect of dietary soyabean, P< 0.05; effect of DES, P< 0.001; interaction between
dietary soyabean and DES, P< 0.001. Adapted from MaÈkelaÈ et al. (1995).
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Although the clinical implications of these studies in premenopausal women are under
debate, when the in vitro, animal, and human data are considered, it is dif®cult to conclude that
soyabean and=or iso¯avones are necessarily anti-oestrogenic in premenopausal women. As
noted previously, however, genistein inhibits the growth of both oestrogen receptor-positive
and-negative breast cancer cells (Peterson & Barnes, 1991). Thus, even without exerting anti-
oestrogenic effects, soyabean=genistein may decrease breast cancer risk through non-hormonal
mechanisms (see earlier and Fig. 5).
Epidemiology. Although several epidemiological studies have considered the relation-
ship between soyabean intake and breast cancer risk, most were conducted before the increased
interest in the potential anticancer effects of soyabean foods. Consequently, especially in the
earlier studies, some concern exists about the completeness of the dietary soyabean data. Not
surprisingly, nearly all of the epidemiological studies were conducted in Asia.
The ®rst published study, conducted in Japan, was a case±control study involving 212
cases and equal numbers of hospitalized and neighbourhood controls, that was actually
designed to examine the effects of dietary fat on breast cancer risk (Hirohata et al. 1985). No
association was noted between fat intake from soyabean products and cancer risk, although
speci®c information on soyabean intake was not provided. In a prospective study in Hawaii
involving nearly 7000 subjects, Nomura et al. (1978) used the soyabean intakes of the men in
this cohort as a surrogate for their wives' intakes to examine the effect of soyabean on breast
cancer risk. Dietary uptake was recorded during two different time periods, 1965±8 and 1971±
5. No association during the ®rst time period was found, but during the second period, an
inverse association was noted between intake of miso soup and cancer risk and a trend for a
decreased risk for tofu intake. In agreement with these ®ndings, in a prospective study, Hir-
ayama (1986) found a signi®cant graded inverse association between the intake of soyabean
paste soup and subsequent risk of breast cancer among 142 857 women in Japan followed for
17 years.
More recently, a case±control study by Lee et al. (1991) in Singapore (n 200 cases, 420
controls) found that the regular consumption of soyabean foods was associated with a marked
decreased risk of breast cancer in premenopausal women (upper ®fth v. lowest ®fth of the
intake of total soyabean products; odds ratio 039, 95 % CI 019, 077; P< 002), but not in
postmenopausal women. Similarly, a Japanese case±control study (n 1186 cases, 23 163
controls) also found that soyabean intake (tofu intake ^ 3 times=week v. < 3 times=week) was
associated with a decreased risk of breast cancer in premenopausal women (odds ratio 081,
95 % CI 065, 099; P< 005), but not postmenopausal women (Hirose et al. 1995). In contrast
to these studies, a case±control study involving two different locations in China, Shanghai (n
534 cases, 534 controls) and Tianjin (n 300 cases, 300 controls), failed to ®nd an association
between soyabean food intake and breast cancer risk in either pre- or postmenopausal women
(Yuan et al. 1995).
The only case±control study (n 596 cases, 958 controls) thus far conducted in the USA to
examine the relationship between soyabean intake and breast cancer risk found that tofu
consumption was protective in both pre- (adjusted odds ratio 067) and postmenopausal Asian
women (adjusted odds ratio 060) (Wu et al. 1996). However, the overall intake of tofu among
the subjects in this study was relatively low; the highest quartile of intake included women who
consumed tofu as little as ®fty-®ve times=year. Also, tofu was protective primarily in Asian
women born in Asia who migrated to the West and not in Asians born in the USA (Wu et al.
1998). Finally, in the prospective Iowa Women's Study involving over 34 000 women, after 8
years of follow-up, tofu intake was associated with a modest decrease (adjusted relative risk
076; no consumption v. any consumption) in postmenopausal breast cancer risk. This differ-
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ence was not statistically signi®cant (P 022) (Greenstein et al. 1996). Not unexpectedly,
however, only 29 % of the cohort reported eating any tofu.
In addition to the limited number of epidemiological studies that quanti®ed soyabean
intake, Ingram et al. (1997), in a study involving 144 pairs of cases and population controls
matched for age and area of residence, found an inverse relationship between the risk of both
pre- and postmenopausal breast cancer and the urinary excretion of iso¯avonoids (three 24 h
collections; for cases, urine samples were collected before surgery). After controlling for age at
menarche, alcohol consumption and fat intake, the adjusted odds ratio (lowest v. highest
quartile) for equol, an iso¯avan, was 027 (P 0009). However, urinary excretion of genistein
was not measured and the interassay CV for the control urine pool sample for the individual
phyto-oestrogens ranged from 109 % to 426 %. Also, no markers were included to assess the
completeness of urine collections. Perhaps more importantly, based on the urinary collection of
daidzein and equol, soyabean consumption even in the highest quartile of intake was quite
modest.
Animal studies. Several animal studies have examined the effect of diets containing
soyabean iso¯avones on experimental mammary cancer (Table 5); four studies used diets that
included soyabean-protein isolate (> 90 % soyabean protein), four non-fermented, whole
soyabean products, two miso, and two iso¯avones. Overall, these studies provide modest
support for a protective effect of soyabean=iso¯avones.
Of the four studies using soyabean protein isolate, two found a protective effect (Barnes
et al. 1990; Hawrylewicz et al. 1991), whereas two did not (Carroll, 1975; Hsueh & Park,
1990). However, neither study in which protective effects were observed reported a reduction
in tumour incidence. Also, in one of those studies (Hawrylewicz et al. 1991) the addition of
methionine to the soyabean diet eliminated much of the difference in tumour number, although
tumour volume was still signi®cantly reduced.
Each of the four studies that used non-fermented, whole soyabean products reported
protective effects (Troll et al. 1980; Gridley et al. 1983; Barnes et al. 1990; Gotoh et al. 1998b).
In the study by Troll et al. (1980), however, raw soyabeans were used and the body weight of
soyabean-fed rats was 10 % lower than that of control animals. Also, no effects on tumour
incidence were found in any of the other three studies. In the study by Barnes et al. (1990),
although tumour number was reduced by approximately 50 %, no dose response was observed
among the three different diets containing 50, 100 and 200 g soyabean=kg diet). Furthermore,
the reduction of tumour number in the study by Gotoh et al. (1998b) appeared to be a function
primarily of a delay in tumour appearance. Finally, although Gridley et al. (1983) found that
textured soyabean protein did slightly increase the latency period for spontaneous tumours,
®nal cancer incidence was not affected.
Two studies incorporated the fermented soyabean product, miso, into their laboratory diets.
In one study, Baggott et al. (1990) found that the number of dimethylbenz(a)anthracene-
induced mammary tumours was decreased by approximately 30 % in rats fed on a diet con-
taining 200 g miso=kg diet. In the other study, by Gotoh et al. (1998b), a diet containing 100 g
miso=kg diet reduced N-nitroso-N-methylurea (MNU)-induced mammary tumour number by
about 50 %. As pointed out earlier, however, tumour inhibition appeared to be related to a delay
in tumour appearance in the rats consuming whole soyabeans. In a follow-up study (Gotoh et
al. 1998a), a diet containing 100 g miso=kg diet was again shown to be effective in reducing
tumour number by about 50 %. In addition, tamoxifen also signi®cantly reduced tumour
number, and the combination of tamoxifen and miso acted synergistically to inhibit tumour
development. This combination signi®cantly reduced both tumour incidence and number. The
authors speculated that the increase in the number of oestrogen receptors in the tumour
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increased the hormone dependency of the tumours, thereby potentiating the effects of the anti-
oestrogen, tamoxifen. Furthermore, in a study designed to examine possible therapeutic effects,
the combination of tamoxifen and miso signi®cantly inhibited tumour size, when administered
after tumours had already formed, in comparison with the control and tamoxifen groups.
Interestingly, Baggott et al. (1990) attributed the protective effects of miso to the high Na
content of this food.
An additional two studies examined the effects of isolated iso¯avones on chemically-induced
mammary cancer in mature animals. Constantinou et al. (1996) found that neither isolated gen-
istein (08 mg=d) nor daidzein affected MNU-induced mammary tumour incidence. Although both
iso¯avones reduced tumour number by approximately 20 %, this reduction was not statistically
signi®cant. Similarly, Murillo et al. (1998) found that genistein had no effect on MNU-induced
mammary carcinogenesis. When genistein was combined with the synthetic iso¯avone, ipri-
¯avone, which also was ineffective by itself, tumour number was reduced by approximately 50 %.
In contrast to the unimpressive effects of iso¯avones in adult animals, several reports have
shown that early exposure, during either the neonatal or prepubertal period of life, to genistein
(subcutaneous or dietary administration) markedly inhibits the development of dimethyl-
benz(a)anthracene-induced mammary tumours in rodents and increases the latency period
(Brown & Lamartiniere, 1995; Lamartiniere et al. 1995; Murrill et al. 1996). Genistein appears
to reduce carcinogenesis by stimulating mammary development and making this tissue less
sensitive to the carcinogenic effects of dimethylbenz(a)anthracene. Finally, genistein
(075 g=kg diet) was found to stimulate the growth of MCF-7 (human breast cancer cell line)
cells implanted into OVX athymic mice (Hsieh et al. 1996). The growth of oestrogen-inde-
pendent MDA-MB-231 cells, a human breast cancer cell line, however, was inhibited by a high
(3 g=kg diet), but not a low (075 g=kg diet), dose of genistein, although food intake (but not
body weight) was reduced by 10 % at the higher level of genistein (Santell et al. 1998).
Overall strength of the evidence for breast cancer. Although an intriguing hypothesis,
the scienti®c evidence is only modestly supportive that the adult consumption of soyabean
reduces breast cancer. The limited epidemiological data are somewhat supportive of the
hypothesis, but mostly for premenopausal breast cancer. In fact, one case±control study (Wu et
al. 1996) found soyabean intake to be inversely related to risk of postmenopausal breast cancer
whereas three studies that included four different populations did not (Lee et al. 1991; Hirose et
al. 1995; Yuan et al. 1995). Furthermore, in the one study in which soyabean was protective
against postmenopausal breast cancer, protection was limited primarily to Asian immigrants,
not USA-born Asians. Although Ingram et al. (1997) found the urinary excretion of equol to be
inversely related to breast cancer risk, it would appear that overall soyabean intake in that study
was quite low. Also, unfortunately, in general in western populations it is dif®cult to control for
all differences between soyabean food consumers and non-consumers that potentially affect
breast cancer risk since signi®cant amounts of soyabean foods are not commonly consumed.
Perhaps soyabean intake contributes to the low breast cancer mortality rates in Asian countries,
not simply because of the consumption of soyabean foods in adulthood, but because of the
soyabean foods these women ®rst consumed as young girls.
The most impressive evidence comes from the animal studies showing that exposure to
genistein during the early stages of life reduces the later development of chemically-induced
mammary cancer. However, ®ndings from studies of adult animals in which isolated iso-
¯avones were administered were not impressive. In general, those studies showing a reduction
in carcinogenesis found only that tumour number, not tumour incidence, was affected. Also as
discussed previously, there were concerns about many of the studies in which soyabean was
shown to be protective.
104 J. J. B. Anderson et al.
https://www.cambridge.org/core/terms. https://doi.org/10.1079/095442299108728875
Downloaded from https://www.cambridge.org/core. IP address: 136.56.14.111, on 02 Feb 2021 at 21:28:43, subject to the Cambridge Core terms of use, available at
Clearly, genistein inhibits both oestrogen-dependent and oestrogen-independent breast
cancer cells in vitro. However, the genistein concentration required to inhibit cell growth may
be higher than the concentration that can be achieved in vivo in humans consuming soyabean
foods and is probably higher than the genistein concentration of free-living Japanese people. A
plasma genistein concentration of 276 nmol=l was observed in free-living Japanese men (n 14)
(Adlercreutz et al. 1993), but in humans fed on soyabean foods and isolated genistein, plasma
genistein concentrations have reached the low micromolar level (Xu et al. 1994, 1995; King &
Bursill, 1998). However, most of the genistein molecules in plasma are either bound to protein
(Arnold et al. 1996; Martin et al. 1996) or conjugated with glucuronic acid (Adlercreutz et al.
1995) and are, therefore, likely to be biologically inactive. It is worth noting, however, that
Peterson & Barnes (1996) found that much lower genistein concentrations are required to
inhibit the growth of non-transformed human breast epithelial cells in comparison with breast
cancer cells.
It is clear therefore that given the potent in vitro effects of genistein, and the protective
effects shown by some animal and epidemiological studies, little question remains that the
relationship between soyabean intake and breast cancer risk warrants further investigation.
Prostate cancer
Prostate cancer mortality rates vary markedly among countries. An interesting observation
related to the occurrence of prostate cancer is that clinical prostate cancer rates vary much more
than the rates of latent prostate cancer. For example, the incidence of clinical prostate cancer in
the USA among white men is 10±15-fold higher than the Japanese rate, whereas the overall
incidence of latent prostate cancer is only about 50 % higher (Yatani et al. 1989). Also, recent
work suggests that the Japanese incidence of prostate cancer may actually be under-diagnosed
by as much as 80 %, making the true ratio of incidence to mortality much higher in Japan than
in the West (Shibata et al. 1997). These observations suggest that in some populations, such as
the Japanese, the growth of prostate tumours is slower and=or that the onset of prostate tumours
occurs later in life. Speculation abounds that the intake of soyabean foods may be one factor
contributing to the low Japanese prostate cancer mortality rate, although the data in support of
this hypothesis, while intriguing, are limited.
Epidemiological studies. Not surprisingly, limited human data exist upon which to
evaluate the soyabean±prostate cancer hypothesis, as only a few epidemiological studies have
been conducted in this area. In a Japanese cohort, no signi®cant association between soyabean
paste soup and prostate cancer risk (Hirayama, 1979) was noted nor was a consistent rela-
tionship for miso soup with prostate cancer evident when comparing cancer patients with
patients with hyperplastic disease and controls (Oishi et al. 1988). In contrast, a prospective
study by Severson et al. (1989) involving 7999 men in Hawaii who were followed for 18±21
years found that the consumption of tofu was associated with a markedly reduced risk of
prostate cancer (21=week v. 35=week; age- adjusted relative risk 035), although this difference
did not quite reach statistical signi®cance (P 0054), and the number of men with tumours in
each of the tertiles was quite small.
Of potential relevance to the effects of iso¯avones on prostate cancer risk is the ®nding that
not only are iso¯avone levels higher in prostatic ¯uid in men from soyabean food-consuming
countries but that iso¯avones appear to be concentrated by about twofold in the prostatic ¯uid
relative to plasma (Morton et al. 1997). Also worthy of note is a recent report that signi®cant
apoptosis occurred in the prostatic specimen from a man with adenocarcinoma who had taken
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iso¯avones (160 mg=d) derived from red clover (Trifolium pratense) one week before surgery
(Stephens, 1997). The red clover extract contained both genistein and daidzein as well as the
methylated iso¯avones, biochanin-A and formononetin, from which genistein and daidzein,
respectively, are derived. Finally, in a short-term study by S Barnes (unpublished results),
soyabean intake did not affect prostate-speci®c antigen levels in men with elevated prostate-
speci®c antigen levels.
In vitro effects of genistein. Genistein inhibits the growth of both androgen-dependent
and androgen-independent prostate cancer cells in vitro (Peterson & Barnes, 1993; Naik et al.
1994; Kyle et al. 1997). Also, as noted previously, independent of cell growth, genistein has
been shown to inhibit the metastatic potential of prostate cancer cells, an effect that is asso-
ciated with a decrease in the tyrosine phosphorylation of an unidenti®ed protein (SantibaÂnÄez et
al. 1997).
In addition to the effects of genistein on signal transduction noted previously, other
mechanisms by which genistein=iso¯avones could reduce prostate cancer risk also are oper-
ating. For example, oestrogens have been used successfully as a form of hormone therapy for
metastatic prostate cancer (Pienta & Esper, 1993); thus, theoretically, the oestrogenic effects of
iso¯avones may be protective. Also, some data indicate that in genital skin ®broblasts and
benign hyperplastic prostate tissue, genistein inhibits the activity of 5a-reductase (EC 1.1.1.64),
the enzyme that converts testosterone into dihydrotestosterone, which stimulates the growth of
prostate tissue (Evans et al. 1995). Ross et al. (1992) have shown that biomarkers of 5a-
reductase activity are higher in Caucasian and black men compared with Japanese subjects, a
®nding that may contribute to differences in prostate cancer rates between these populations.
The in vitro data from Evans et al. (1995) are consistent with ®ndings from Lu et al. (1996b),
who reported that after one month of soyabean milk consumption (104 litres=d), serum levels
of 3a,17b-androstanediol glucuronide, a metabolite of dihydrotestosterone, were signi®cantly
reduced.
Animal studies. Only recently has the effect of soyabean on prostate cancer in laboratory
animals been studied. One study relevant to this topic, but which did not involve prostate
cancer per se, found that after 9 months of feeding a diet containing soyabean to Han-NMRI
mice, the incidence of prostatic dysplasia, which may be viewed as a pre-neoplastic prostate
lesion, was markedly reduced compared with the incidence in mice not fed on soyabean (30 %
v. 80 %, P< 004) (MaÈkelaÈ et al. 1995). At 12 months, however, the difference between the two
groups was reduced (64 % v. 86 %). These ®ndings are consistent not only with the epide-
miological data noted above, but also with the results of a study of MNU- induced prostate
tumours in Lobund-Wistar rats (Pollard & Luckert, 1997). Rats fed on a diet containing
soyabean, but with a very low level of iso¯avones, had latency periods of 73 (pre-MNU group)
and 93 months (post-MNU group), compared with 100 (pre-MNU group) and 106 months
(post-MNU group) for animals fed on a diet containing soyabean with a high iso¯avone content
(Fig. 10).
Five studies were identi®ed that examined the effect of soyabean=genistein on tumour
development in rats implanted with prostate cancer cells (Naik et al. 1994; Wang et al. 1995;
Schleicher et al. 1996; Zhang et al. 1997a; Zhou et al. 1998). Four of these studies, all of which
have been published in abstract form only, reported protective effects. Zhang et al. (1997a)
found that in rats fed on a diet containing soyabean ¯our (330 g=kg diet) and implanted with
Dunning R3327 PAP (rat prostate adenocarcinoma) tumours, tumour growth was signi®cantly
retarded at 16 weeks compared with animals fed on the control diet. Similarly, Schleicher et al.
(1996) found that genistein (50 mg=kg body weight), given under the skin in the dorsal scapular
area every 12 h starting at the time of tumour cell transplantation, inhibited the development of
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prostate tumours in rats implanted with prostate carcinoma cells. Rats given genistein devel-
oped fewer tumours and fewer invasive tumours and no genistein-treated animals developed
lung metastases. In agreement with these studies, Zhou et al. (1998) found that the addition of
an iso¯avone rich concentrate to an AIN-76 diet (Anonymous, 1977) signi®cantly reduced
tumour volume in SCID (Severe, Combined ImmunoDe®ciency) mice inoculated sub-
cutaneously with 26 106 LNCaP (human prostate adenocarcinoma cell line) cells. Finally,
Wang et al. (1995) found that dietary genistein (1 g=kg diet), when added to a high-fat (405 %
of energy) diet, inhibited the growth of LNCaP cells implanted into nude mice.
Insight into a possible mechanism for the inhibitory effects of genistein against implanted
prostate cancer cells comes from Dalu et al. (1996) who found that in Lobund-Wistar rats,
dietary genistein (1 g genistein=kg diet) decreased the weight of the dorsolateral and ventral
prostates and inhibited the expression of tyrosine-phosphorylated proteins. This study is the
®rst to demonstrate that, in vivo, genistein inhibits a key cellular pathway. Related to this
®nding are those of Geller et al. (1998) who found that genistein inhibited the incorporation of
[3H]thymidine (a measure of tissue growth) in a dose-dependent fashion (at concentration
ranging from 1±15 mg=ml) by 44 % and 86 % in cultured benign prostate hypertrophy tissue.
In contrast to the favourable results discussed above, Naik et al. (1994) found that,
although genistein inhibited prostate cancer cell growth in vitro, when Copenhagen rats were
injected in the right ¯ank with the metastatic MAT-Lylu prostate cancer cell line, oral doses of
genistein of 007, 0143 and 0285 mg=kg body weight per d did not inhibit the development of
prostate tumours. Higher doses of genistein (0143, 0285 and 0428 mg=kg body weight
per d) injected intraperitoneally also had little effect on tumour growth. The dietary levels used
by Naik et al. (1994) were much lower than the levels used in the studies in which protective
effects were observed, but they more closely approximate human dietary intake.
Fig. 10. Tumour latency period in rats fed on high and low iso¯avone-containing diets. Rats
were fed on a diet that included 200 g=kg soyabean protein isolate containing either 127 mg
genistein and 042 mg daidzein per g protein (high iso¯avone, ( )) or 0077 mg genistein and
0025 mg daidzein per g protein (low iso¯avone, ( )) Tumours were initiated by inoculation with a
single dose of N-nitroso-N-methylurea (MNU) followed by two subcutaneous implants of testos-
terone propionate. Diets were fed either before or following MNU administration. Trials were
terminated 14 months after onset. Adapted from Pollard & Luckert (1997).
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Overall strength of the evidence for prostate cancer. The evidence that soyabean reduces
prostate cancer risk is limited, but the available data tend to be more supportive of a bene®t in
terms of a reduction in prostate cancer risk than they are for breast cancer although this
relationship is still quite speculative. Only a few epidemiological studies have examined this
issue, and although one study did suggest that tofu intake was protective against prostate
cancer, the association did not reach statistical signi®cance (Severson et al. 1989). Several
studies did ®nd that soyabean=genistein inhibited the growth of prostate cancer cells implanted
into rodents (Wang et al. 1995; Schleicher et al. 1996; Zhang et al. 1997a; Zhou et al. 1998),
and one study found that genistein inhibited a key cellular pathway in vivo (Dalu et al. 1996).
However, when a relatively low dose of genistein (in comparison with these studies) was used,
Naik et al. (1994) did not observe growth inhibition in vivo. A very intriguing ®nding reported
by Morton et al. (1997) is that, relative to plasma, iso¯avones appear to be concentrated in the
prostatic ¯uid. This difference in concentration suggests that the relatively high levels of
genistein required to inhibit prostate cancer cell growth in vitro and in vivo may be applicable
to humans consuming soyabean foods.
Discussion
The two primary observations of low breast and prostate cancer rates in Asian countries, where
soyabean foods are consumed at high levels, and high iso¯avone content of soyabeans raised
initial interest in the relationship between soyabean food intake and cancer risk. However, only
within the past 10 years has the diet±prostate cancer linkage been seriously investigated and
establishing diet±cancer relationships has proved to be dif®cult, in part because many of the
data relevant to the soyabean±cancer relationship are con¯icting.
Overall, the evidence is more supportive for a protective effect against prostate cancer than
breast cancer. In addition to the evidence already presented, several intriguing observations
about the possible anticancer effects of soyabean=iso¯avones related to breast, prostate, and
other cancers make further research in this area compelling. For example, genistein has been
shown to inhibit angiogenesis in vitro (Fotsis et al. 1993). Although the concentration of
genistein initially reported to inhibit angiogenesis (IC50, 150 mmol=l) is certainly much higher
than the genistein concentration likely to be achieved in vivo, more recent work has shown that
a much lower (IC50, 8 mM) genistein concentration is effective in inhibiting angiogenesis
(Adlercreutz & Mazur, 1997). A possible explanation for the higher genistein concentration
required to inhibit angiogenesis in the earlier report may have resulted from incomplete
solubilization of genistein in the media.
Results from several recent animal studies also suggest that soyabean=iso¯avones may
inhibit tumour metastases (Yan et al. 1997, 1998; Menon et al. 1998), including the metastases
of human breast cancer cells (Connolly et al. 1997). In addition, daidzein has recently been
shown to enhance immune function in vitro (Wang et al. 1997) and in animals (Zhang et al.
1997b), although Hendrich et al. (1998) did not ®nd an effect of short-term (7 d) soya milk
consumption on natural killer cell activity in young adults. Finally, results from a preliminary
human study indicated that short-term soya milk consumption reduced lymphocyte DNA
damage (Mitchell & Collins, 1998). Thus, a variety of potential mechanisms exists through
which soyabean foods may inhibit the cancer process that are equally applicable to a variety of
cancers (Table 3). Human studies in which the effects of soyabean consumption on biomarkers
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of cancer risk are examined are sorely needed and more research in general is needed before
anything approaching a ®rm conclusion can be made.
Overall conclusions
Investigations of phyto-oestrogens over the previous decade have demonstrated that these
iso¯avone molecules have diverse actions on mammalian cells, largely related to their oes-
trogen-mimetic properties.
Classical genomic actions of oestrogens have been used to explain the positive effects of
these steroid molecules on both cardiovascular and bone tissues. Similarly, the potential for
stimulation of growth of cancer cells in breast and uterine tumours is probably due to their
effects on protein expression. Although the phyto-oestrogens were originally discovered
because of their ability to mimic the actions of oestrogens on reproductive tissues in livestock,
more recent research suggest that many potential effects of both oestrogens and phyto-oes-
trogens may be mediated by either cell-surface steroid receptors or molecules that belong to
intracellular second-messenger systems. Understanding these alternative mechanisms of action
will be critical for de®ning the role of phyto-oestrogens for both their bene®cial and, poten-
tially, adverse effects.
Human studies that are underway will probably demonstrate whether short-term con-
sumption of phyto-oestrogens can produce health-promoting effects on tissue function and
clarify effective doses for various organ systems. The epidemiological studies involving high
soyabean-consuming Asian populations have been based on individuals with a lifetime pattern
of daily intakes of phyto-oestrogen-containing foods from diverse soyabean products. The
evidence that soyabean, with its phyto-oestrogens, is bene®cial for cardiovascular diseases and
its risk factors seems convincing. Likewise, the bene®cial effects of soyabean phyto-oestrogens
on bone are rather consistent, although longer term studies are required to be conclusive.
Whether favourable effects of soyabean phyto-oestrogens on bone and cancer risk exist will
require further information to develop a consensus.
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